MedMira Inc. MMIRF
0.04 USD 0.00 (+0.00%)
At closeNov 9, 2026, 4:00 PM EST
0.035 Day range 0.035
0.0012 52-week range 0.95
- YTD
- +191.67%
- 1 year
- -30.00%
News
accessnewswire.com MedMira Reports Third Quarter Results FY2026 HALIFAX, NS / ACCESS Newswire / June 29, 2026 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2026. Corporate update During Q3 FY2026, the…
accessnewswire.com MedMira Reports Second Quarter Results FY2025 HALIFAX, NS / ACCESS Newswire / April 1, 2026 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2026. Corporate update In Q2 FY2026, the…
accessnewswire.com MedMira Reports First Quarter Results FY2026 HALIFAX, NOVA SCOTIA / ACCESS Newswire / December 30, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2025. Corporate update In Q1…
accessnewswire.com MedMira Reports FY2025 Fourth Quarter and Year End Financial Results HALIFAX, NOVA SCOTIA / ACCESS Newswire / November 28, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2025. Corporate update In…
accessnewswire.com Health Canada Approves MedMira's Reveal(R) Rapid TP Test - Urgent New Tool In The Battle Against Syphilis HALIFAX, NOVA SCOTIA / ACCESS Newswire / August 26, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received approval from Health Canada for its Reveal® TP (Syphilis) Antibody…
accessnewswire.com MedMira Announces Launch of Clinical Trial for Its Multiplo(R) TP/HIV Self-Test in Canada HALIFAX, NS / ACCESS Newswire / July 7, 2025 / MedMira Inc. (MedMira) (TSXV: MIR) and REACH Nexus are excited to announce a clinical trial has officially started earlier than anticipated to evaluate…
accessnewswire.com MedMira Reports Second Quarter Results FY2025 HALIFAX, NS / ACCESS Newswire / June 30, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2025. Corporate update In Q3 FY2025,…
accessnewswire.com MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal(R) G4 HIV-1/2 rapid test for VA, Department of Defense HALIFAX, NS / ACCESS Newswire / April 17, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) and Lovell® Government Services announced today that they have partnered to serve federal healthcare systems such as…
accessnewswire.com MedMira Reports Second Quarter Results FY2025 HALIFAX, NS / ACCESS Newswire / April 1, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2025. Corporate update In Q2 FY2025,…
accessnewswire.com MedMira Announces Partnership with MediGroup Physician Services in the United States HALIFAX, NS / ACCESS Newswire / February 27, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today its partnership with MediGroup, a leader in the US health care industry since 1999. This new…
accessnewswire.com MedMira Announces Exclusive Distribution Agreement with Trimedic Inc. for Canada HALIFAX, NS / ACCESS Newswire / February 25, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today its exclusive distribution agreement with Trimedic Inc. for the Canadian market. This partnership…
accessnewswire.com MedMira Receives Investigational Testing Authorizations for Multiplo(R) TP/HIV Self-Test and Non-Professional Use Applications HALIFAX, NS / ACCESS Newswire / January 21, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received Investigational Testing Authorizations (ITAs) from Health Canada to begin…
accesswire.com MedMira Receives Health Canada Approval for Its Reveal(R) G4 Rapid HIV-1/2 Test for Point-of-Care Use HALIFAX, NS / ACCESSWIRE / January 14, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today the approval from Health Canada for its Reveal®Rapid G4 HIV-1/2 Test…
accesswire.com MedMira Receives Investigational Testing Authorization for its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test HALIFAX, NS / ACCESSWIRE / January 9, 2025 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical…
accesswire.com MedMira Reports First Quarter Results FY2025 HALIFAX, NS / ACCESSWIRE / December 30, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2024. Corporate update During Q1 FY2025,…
accesswire.com MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo®…
accesswire.com MedMira Reports FY2024 Fourth Quarter and Year End Financial Results HALIFAX, NS / ACCESSWIRE / November 28, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2024. Corporate Update In December…
accesswire.com MedMira Announces the appointment of Vice President of Commercial Operations MedMira Inc. continues its North-American expansion plan HALIFAX, NS / ACCESSWIRE / October 3, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) today announced the appointment of Nicole Crenshaw as…
accesswire.com MedMira Reports Third Quarter Results FY2024 HALIFAX, NS / ACCESSWIRE / July 2, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2024. Corporate update In Q3 FY2024, MedMira…
accesswire.com MedMira Announces the Hire of Vice President of Business Development HALIFAX, NS / ACCESSWIRE / April 30, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to announce the expansion of their commercialisation team by welcoming Ms. Rene Bell to the position of…
benzinga.com Stocks That Hit 52-Week Highs On Monday - benzinga.com Stocks That Hit 52-Week Lows On Friday